Design of a Kv1.3×CD25 bispecific antibody to preferentially inhibit activated T cells and ameliorate T-cell-driven colitis. // European Journal of Pharmacology. – URL: https://www.sciencedirect.com/science/article/pii/S0014299926010113?dgcid=rss_sd_all
Design of a Kv1.3×CD25 bispecific antibody to preferentially inhibit activated T cells and ameliorate T-cell-driven colitis. European Journal of Pharmacology. https://www.sciencedirect.com/science/article/pii/S0014299926010113?dgcid=rss_sd_all
“Design of a Kv1.3×CD25 bispecific antibody to preferentially inhibit activated T cells and ameliorate T-cell-driven colitis.” European Journal of Pharmacology.
@article{article12412,
title = {Design of a Kv1.3×CD25 bispecific antibody to preferentially inhibit activated T cells and ameliorate T-cell-driven colitis},
journal = {European Journal of Pharmacology},
url = {https://www.sciencedirect.com/science/article/pii/S0014299926010113?dgcid=rss_sd_all}
}